BiotechTube

Rifaximin + Placebo

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Celiac Disease

Conditions

Celiac Disease

Trial Timeline

Oct 1, 2006 → Apr 1, 2008

NCT ID
NCT01137955

About Rifaximin + Placebo

Rifaximin + Placebo is a pre-clinical stage product being developed by Bausch Health for Celiac Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01137955. Target conditions include Celiac Disease.

Hype Score Breakdown

Clinical
3
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT01951209Pre-clinicalTerminated
NCT00731679Phase 3Completed
NCT00724126Phase 3Completed
NCT00533910Pre-clinicalCompleted
NCT01137955Pre-clinicalCompleted
NCT00298038Phase 3Completed
NCT00742469Phase 3Completed

Competing Products

17 competing products in Celiac Disease

See all competitors
ProductCompanyStageHype Score
DONQ52 + PlaceboChugai PharmaceuticalPhase 1
29
Placebo DONQ52 + DONQ52Chugai PharmaceuticalPhase 2
42
Placebo + RO5459072RochePhase 1
29
CCX282-B + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714AmgenPre-clinical
26
KAN-101 + PlaceboPfizerPhase 2
35
Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part CPfizerPhase 1/2
24
Ritlecitinib + PlaceboPfizerPhase 2
42
PRV-015SanofiPhase 2
35
TIMP-GLIATakeda PharmaceuticalPhase 1
29
TIMP-GLIA + PlaceboTakeda PharmaceuticalPhase 2
35
PTG-100 + PlaceboProtagonist TherapeuticsPhase 1
26
LatiglutenaseAllergy TherapeuticsPhase 2
21
BL-7010 + PlaceboBioLineRxPhase 1/2
22
VTP-1000Barinthus BiotherapeuticsPhase 1
26